Jiangsu Hengrui Medicine

Explore this year's ranking of the 50 companies with the best long-term growth potential.

<p class="p1">Jiangsu Hengrui is the largest pharmaceutical company in China and a leader in cancer treatment drugs and anesthetics for surgery. Its profit rose 14% in the first nine months of 2020, alongside a 15% jump in revenue. The company’s status as a domestic pioneer in novel drug development—its recent drug successes include immunotherapy medications and long-lasting insulin treatments—means it’s been hurt less than some of its peers by the Chinese government’s efforts to drive down generic drug prices. Over the past five years, Jiangsu’s stock is up some 350%.</p>

The Future 50

Fortune's proprietary methodology allows us to zero in on the 50 global firms that are best poised to deliver—and continue delivering—above average gains.

Welcome to the inaugural Fortune Future 50, our new ranking of companies best positioned for breakout growth.

Future 50

Overall Score

Sector

Get insights into Jiangsu Hengrui Medicine including business profile, stock information, news, and rankings from Fortune.

Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine stock chart